HomeCirculationVol. 111, No. 5The “Good Cholesterol” Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBThe “Good Cholesterol”High-Density Lipoprotein Peter P. Toth, MD, PhD Peter P. TothPeter P. Toth From the University of Illinois School of Medicine, Peoria. Search for more papers by this author Originally published8 Feb 2005https://doi.org/10.1161/01.CIR.0000154555.07002.CACirculation. 2005;111:e89–e91Atherosclerosis is an insidious and dangerous disease: a progressive chemical and structural injury to the blood vessels in such critical organs as the heart, brain, and kidney. The hallmark feature of atherosclerosis is the buildup of cholesterol into lesions called plaques that can reduce the flow of blood. When the delivery of blood to heart muscle drops enough, this can result in the development of chest pain or angina. Angina indicates that the heart muscle is not receiving enough oxygen to carry out its pumping functions. Atherosclerotic plaques can also suddenly rupture, develop a blood clot on their surface, and completely choke off a portion of heart muscle. This chain of events frequently results in heart attack or sudden death without warning. Atherosclerotic disease also predisposes people to stroke, peripheral vascular disease, lower-extremity amputation, and loss of kidney function, among other devastating outcomes.Despite all that we have learned in the past 50 years, atherosclerosis remains the No. 1 killer of men and women and the chief reason for loss of quality of life in Western countries. We are, however, gaining ground. Considerable research has revealed the importance of factors that increase an individual’s risk for developing this disease. Among the most important of these risk factors are elevated blood pressure, diabetes mellitus, obesity, inactivity, smoking, and cholesterol levels.When your physician measures your cholesterol level, he or she is looking at your lipid profile, which comprises low-density lipoprotein cholesterol (LDL-C, or the “bad” cholesterol), triglycerides (blood fats), and high-density lipoprotein cholesterol (HDL-C, or the “good” cholesterol). In a general way, when it comes to measurement of your LDL-C and triglyceride values, a lower value is better because these lipids drive the development and progression of atherosclerosis. In sharp contrast, when it comes to HDL-C, with few exceptions, a higher value is better because HDL-C is beneficial and protects patients from the development and progression of atherosclerotic disease.HDL and Cardiovascular Disease RiskStudies of both men and women worldwide have demonstrated that the risk for atherosclerotic disease is inversely related to blood levels of HDL-C; that is, the higher your HDL, the lower your risk. On the other hand, the lower your HDL-C (1 milligram HDL-C per 1 deciliter of blood), the higher your risk. As shown in the Framingham Heart Study, this relationship holds across a broad range of LDL-C levels. Even in patients whose LDL-C is 100 mg/dL (considered by many experts to be an optimal level of “bad” cholesterol), as HDL-C drops, the risk of developing atherosclerosis increases continuously. Consequently, you are at increased risk for heart disease or stroke if your HDL-C is low, even if your LDL-C or total cholesterol is well controlled. Studies have shown that for every 1-mg/dL rise in HDL-C (1 milligram HDL-C per 1 deciliter of blood), the risk for developing cardiovascular disease decreases by 2% to 3%.How is a low HDL-C defined? According to the National Cholesterol Education Program, a group comprising the foremost authorities on cholesterol in the United States, a low HDL-C is defined as a level less than 40 mg/dL.1 An expert panel convened by the American Heart Association has recently concluded that in women, HDL is low when it is below 50 mg/dL.2 Among patients with diabetes, the American Diabetes Association recommends that HDL-C be above 40 and 50 mg/dL for men and women, respectively.3Low levels of HDL-C (see Table 1) are present in millions of men and women in the United States. Because of the rising epidemic of obesity and diabetes, the number of individuals whose HDL-C is low is increasing every year. On the basis of the results of your lipid profile, your doctor may recommend the initiation of lifestyle modification and, if necessary, may couple these measures with medications to help raise your HDL-C (discussed below). TABLE 1. Definition of Low HDL-CMen<40 mg/dLWomen<50 mg/dLBeneficial Effects of HDLHDL-C is beneficial for a number of reasons. The most important is its ability to drive a process called “reverse cholesterol transport.”4 HDL is something of a mop in that it helps to extract excess cholesterol deposited in blood vessel walls and deliver it back to the liver for elimination through the gastrointestinal tract (see the Figure). In general, the higher your HDL-C, the greater your capacity to remove cholesterol and prevent dangerous blockages from developing in your blood vessels. HDL-C helps to keep your blood vessels widened (dilated), thereby promoting better blood flow. HDL-C also reduces blood vessel injury through its antioxidant and antiinflammatory functions, among other effects. Download figureDownload PowerPointSchematic depiction of reverse cholesterol transport. As HDL-C in blood penetrates atherosclerotic plaque in the vessel wall, it mobilizes and binds cholesterol and transports it back to the liver for elimination through the gastrointestinal tract.Lifestyle Modification and HDL-CLifestyle modification is always frontline therapy for men and women with low HDL-C. Obesity, cigarette smoking, and a sedentary lifestyle all reduce blood levels of HDL-C.5,6 In contrast, weight loss, smoking cessation, and exercise all promote raising HDL-C. If you are obese and then lose weight, the greater your weight loss and reduction in the circumference of your waist, the greater will be the elevation in your HDL-C level. The more you exercise, the more your HDL-C will increase. If you quit smoking, then your HDL-C can increase up to 15% to 20%, an elevation on par with some of the best drugs available for raising HDL-C. Increased fish7 and reduced carbohydrate consumption both are associated with higher HDL-C. The so-called Mediterranean diet (a diet enriched with fruits, vegetables, whole grains, olive oil, and legumes) is associated with increased HDL-C.8 Alcohol consumption can raise HDL-C significantly,6 but this benefit must be counterbalanced with knowledge of the risks of alcohol consumption. In general, the average patient could responsibly consume 2 to 6 ounces of wine with each evening’s meal.9Medications That Raise HDL-CFor many patients, lifestyle modification may not be enough to achieve adequate elevations in HDL-C. Your heredity plays an important role in regulating the level of your HDL-C. Mutations in one or more genes can give some people a very high level of HDL-C and predispose others to very low levels of HDL-C. Many patients will require the combination of medication with lifestyle modification.A number of medications can have an impact on blood levels of HDL-C.10 The statins have been shown to reduce the risk of heart attack and death in patients with high LDL-C and low HDL-C. Fibrates (gemfibrozil, fenofibrate) are an effective therapy for patients with high triglycerides and low HDL-C. Niacin is the most potent drug currently available for raising HDL-C and has been shown to reduce the risk of heart attack and stroke in patients with heart disease. Several forms of niacin are available, but dietary-supplement niacin must not be substituted for the niacin that your doctor prescribes because the supplement can cause significant liver injury. When taking a statin and niacin in combination, patients with low HDL-C should not take vitamin E, vitamin C, or beta-carotene supplements because these agents appear to impair the ability of statins and niacin to raise HDL-C. If you are asked to stop taking your antioxidant vitamins, you will not be missing out on much. In several studies, antioxidant vitamins had no effect on risk for cardiovascular disease.Fish oil supplements enriched with omega-3 fatty acids can raise HDL-C.11 If you are diabetic, the thiazolidinedione class of drugs has also been shown to increase blood levels of HDL-C. Your doctor may prescribe one or more drugs simultaneously to treat your low HDL-C, depending on your overall clinical picture and the results of other components of your lipid profile (see Table 2). TABLE 2. Measures to Raise HDL-CLifestyle ChangesWeight LossAerobic exerciseSmoking cesationMediterranean diet, increased fish/reduced carbohydrate consumptionWine (2–6 oz) with evening mealsMedicationsStatinsFibratesNiacinFish oils enriched with omega-3 fatty acidsThiazolidinedionesConclusionHDL-C is the “good” cholesterol because it exerts multiple beneficial functions within the cardiovascular system. Higher levels are more beneficial, and your physician should not undertake any therapeutic measures to reduce your HDL-C. Raising HDL-C can be challenging, but if you persist in the implementation of lifestyle modification and take your medications as prescribed, you can significantly alter your risk of cardiovascular disease. After beginning medication, you must continue with lifestyle modification to achieve long-term success in raising HDL-C. Given the wide prevalence of low HDL-C and its importance as a risk factor, a number of therapies are being developed in an effort to raise HDL-C even more effectively. The introduction of these drugs will constitute a major advance in heart disease prevention.Additional Web Resources on HDL-CHeart Center Online web site. Available at: http://www.heartcenteronline.com/myheartdr/common/articles.cfm?ARTID=505.American Heart Association web site. Available at: http://www.americanheart.org/presenter.jhtml?identifier=183.MedicineNet.com web site. Available at: http://www.medicinenet.com/cholesterol/article.htm.American Association for Clinical Chemistry web site. Available at: http://www.medicinenet.com/cholesterol/article.htm.DisclosureDr Toth is a consultant to AstraZeneca, Merck, and GlaxoSmithKline, and a member of the speakers’ bureaus of AstraZeneca, Merck, Kos Pharmaceuticals, Novartis, and Pfizer.FootnotesCorrespondence to Dr Peter Toth, Sterling Rock Falls Clinic, 101 E Miller Rd, Sterling, IL 61081. E-mail [email protected] References 1 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486–2497.CrossrefMedlineGoogle Scholar2 Mosca L, Appel LJ, Benjamin EJ, Berra K, Chandra-Strobos N, Fabunmi RP, Grady D, Haan CK, Hayes SN, Judelson DR, Keenan NL, McBride P, Oparil S, Ouyang P, Oz MC, Mendelsohn ME, Pasternak RC, Pinn VW, Robertson RM, Schenck-Gustafsson K, Sila CA, Smith SC Jr, Sopko G, Taylor AL, Walsh BW, Wenger NK, Williams CL; American Heart Association. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. 2004; 109: 672–693.LinkGoogle Scholar3 Haffner SM; American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004; 27: S68–S71.CrossrefMedlineGoogle Scholar4 Toth PP. Reverse cholesterol transport: high-density lipoprotein’s magnificent mile. Curr Atheroscler Rep. 2003; 5: 386–393.CrossrefMedlineGoogle Scholar5 Wilsgaard T, Arnesen E. Change in serum lipids and body mass index by age, sex, and smoking status: the Tromso study 1986–1995. Ann Epidemiol. 2004; 14: 265–273.CrossrefMedlineGoogle Scholar6 Ellison RC, Zhang Y, Qureshi MM, Knox S, Arnett DK, Province MA; Investigators of the NHLBI Family Heart Study. Lifestyle determinants of high-density lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am Heart J. 2004; 147: 529–535.CrossrefMedlineGoogle Scholar7 Dewailly E, Blanchet C, Gingras S, Lemieux S, Holub BJ. Fish consumption and blood lipids in three ethnic groups of Quebec (Canada). Lipids. 2003; 38: 359–365.CrossrefMedlineGoogle Scholar8 Knoops KT, de Groot LC, Kromhout D, Perrin AE, Moreiras-Varela O, Menotti A, van Staveren WA. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA. 2004; 292: 1433–1439.CrossrefMedlineGoogle Scholar9 Szmitko PE, Verma S. Red wine and your heart. Circulation. 2005; 111: e10–e11.LinkGoogle Scholar10 Toth PP. High-density lipoprotein and cardiovascular risk. Circulation. 2004; 109: 1809–1812.LinkGoogle Scholar11 Calabresi L, Villa B, Canavesi M, Sirtori CR, James RW, Bernini F, Franceschini G. An omega-3 polyunsaturated fatty acid concentrate increases plasma high-density lipoprotein 2 cholesterol and paraoxonase levels in patients with familial combined hyperlipidemia. Metabolism. 2004; 53: 153–158.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited ByLi H, Qian F, Zuo Y, Yuan J, Chen S, Wu S and Wang A (2022) U-Shaped Relationship of High-Density Lipoprotein Cholesterol and Incidence of Total, Ischemic and Hemorrhagic Stroke: A Prospective Cohort Study, Stroke, 53:5, (1624-1632), Online publication date: 1-May-2022. Ahn S, Yoon T, Song J, Park Y and Lee S (2020) Lipid Profiles in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis: A Cross-sectional Analysis, Journal of Rheumatic Diseases, 10.4078/jrd.2020.27.4.261, 27:4, (261-269), Online publication date: 1-Oct-2020. Adegun M and Adelabu D (2020) Nitrogen Utilization and Blood Analysis of West African Dwarf Rams Fed Yam Peel Based Diets, Asian Journal of Animal Sciences, 10.3923/ajas.2020.103.110, 14:3, (103-110), Online publication date: 15-Jun-2020. Chen L, Yao Y, Jin C, Wu S, Liu Q, Li J, Ma Y, Xu Y and Zhong Y (2019) Integrative genomic analysis identified common regulatory networks underlying the correlation between coronary artery disease and plasma lipid levels, BMC Cardiovascular Disorders, 10.1186/s12872-019-01271-9, 19:1, Online publication date: 1-Dec-2019. Singh N and Rao G (2019) Emerging role of 12/15-Lipoxygenase (ALOX15) in human pathologies, Progress in Lipid Research, 10.1016/j.plipres.2018.11.001, 73, (28-45), Online publication date: 1-Jan-2019. Meng W, Adam L, Behnia K, Zhao L, Yang R, Kopcho L, Locke G, Taylor D, Yin X, Wexler R and Finlay H (2019) Benzothiazole-based compounds as potent endothelial lipase inhibitors, Bioorganic & Medicinal Chemistry Letters, 10.1016/j.bmcl.2019.126673, 29:20, (126673), Online publication date: 1-Oct-2019. Kim S, Johnson J, Jiang J, Parkhurst B, Phillips M, Pi Z, Qiao J, Tora G, Ye Chen A, Liu E, Yin X, Yang R, Zhao L, Taylor D, Basso M, Behnia K, Onorato J, Chen X, Abell L, Lu H, Locke G, Caporuscio C, Adam L, Gordon D, Wexler R and Finlay H (2019) Identification of substituted benzothiazole sulfones as potent and selective inhibitors of endothelial lipase, Bioorganic & Medicinal Chemistry Letters, 10.1016/j.bmcl.2019.05.048, 29:15, (1918-1921), Online publication date: 1-Aug-2019. Harada K, Kikuchi R, Suzuki S, Tanaka A, Aoki T, Iwakawa N, Kojima H, Hirayama K, Mitsuda T, Sumi T, Negishi Y, Ishii H and Murohara T (2018) Impact of high-density lipoprotein 3 cholesterol subfraction on periprocedural myocardial injury in patients who underwent elective percutaneous coronary intervention, Lipids in Health and Disease, 10.1186/s12944-018-0670-3, 17:1, Online publication date: 1-Dec-2018. Jeemon P, Gupta R, Onen C, Adler A, Gaziano T, Prabhakaran D and Poulter N (2017) Management of Hypertension and Dyslipidemia for Primary Prevention of Cardiovascular Disease Disease Control Priorities, Third Edition (Volume 5): Cardiovascular, Respiratory, and Related Disorders, 10.1596/978-1-4648-0518-9_ch22, (389-404), Online publication date: 17-Nov-2017. Charlet K and Heinz A (2016) Harm reduction -a systematic review on effects of alcohol reduction on physical and mental symptoms , Addiction Biology, 10.1111/adb.12414, 22:5, (1119-1159), Online publication date: 1-Sep-2017. Kunutsor S, Kieneker L, Bakker S, James R and Dullaart R (2017) The inverse association of HDL-cholesterol with future risk of hypertension is not modified by its antioxidant constituent, paraoxonase-1: The PREVEND prospective cohort study, Atherosclerosis, 10.1016/j.atherosclerosis.2017.06.353, 263, (219-226), Online publication date: 1-Aug-2017. Parish E and Grainger W (2017) 4 Chemistry of Waxes and Sterols Food Lipids, 10.1201/9781315151854-5, (109-130), Online publication date: 23-Mar-2017. Martini D, Rossi S, Biasini B, Zavaroni I, Bedogni G, Musci M, Pruneti C, Passeri G, Ventura M, Di Nuzzo S, Galli D, Mirandola P, Vitale M, Dei Cas A, Bonadonna R and Del Rio D (2017) Claimed effects, outcome variables and methods of measurement for health claims proposed under European Community Regulation 1924/2006 in the framework of protection against oxidative damage and cardiovascular health, Nutrition, Metabolism and Cardiovascular Diseases, 10.1016/j.numecd.2017.01.008, 27:6, (473-503), Online publication date: 1-Jun-2017. Choi H, Kim H, Stefani K, Lee J, Yoon Y, Lee E, Kim K, Rhee Y, Youm Y and Kim C (2017) Serum high-density lipoprotein cholesterol concentration and functional state: The Korean Urban Rural Elderly (KURE) Study, Archives of Gerontology and Geriatrics, 10.1016/j.archger.2017.04.002, 71, (115-121), Online publication date: 1-Jul-2017. Liu Z, Zhang Y, Zhang R, Gu L and Chen X (2017) Promotion of classic neutral bile acids synthesis pathway is responsible for cholesterol-lowing effect of Si-miao-yong-an decoction: Application of LC–MS/MS method to determine 6 major bile acids in rat liver and plasma, Journal of Pharmaceutical and Biomedical Analysis, 10.1016/j.jpba.2016.12.021, 135, (167-175), Online publication date: 1-Feb-2017. O’Brien L, Chen Q, Savas J, Lesnefsky E and Gorgey A (2017) Skeletal muscle mitochondrial mass is linked to lipid and metabolic profile in individuals with spinal cord injury, European Journal of Applied Physiology, 10.1007/s00421-017-3687-9, 117:11, (2137-2147), Online publication date: 1-Nov-2017. Stillwell W (2016) Membrane Biogenesis An Introduction to Biological Membranes, 10.1016/B978-0-444-63772-7.00014-2, (315-329), . Yang W, She L, Yu K, Yan S, Zhang X, Tian X, Ma S and Zhang X (2016)(2016) Jatrorrhizine hydrochloride attenuates hyperlipidemia in a high-fat diet-induced obesity mouse model, Molecular Medicine Reports, 10.3892/mmr.2016.5634, 14:4, (3277-3284), Online publication date: 1-Oct-2016. Vasundhara Devi D and Deedi M K (2016) A STUDY OF NON-ENZYMATIC ANTIOXIDANT STATUS IN ACUTE MYOCARDIAL INFARCTION PATIENTS WITH METABOLIC SYNDROME ABNORMALITIES, Journal of Evolution of Medical and Dental Sciences, 10.14260/Jemds/2016/1564, 5:94, (6909-6914), Online publication date: 23-Nov-2016. Giri A, Kanawjia S, Pothuraju R and Kapila S (2014) Effect of inulin incorporated processed cheese spread on lipid profile of blood serum and liver in rats, Dairy Science & Technology, 10.1007/s13594-014-0191-4, 95:2, (135-149), Online publication date: 1-Mar-2015. Slopen N, Non A, Williams D, Roberts A and Albert M (2014) Childhood Adversity, Adult Neighborhood Context, and Cumulative Biological Risk for Chronic Diseases in Adulthood, Psychosomatic Medicine, 10.1097/PSY.0000000000000081, 76:7, (481-489), Online publication date: 1-Sep-2014. Rizvi N and Nagra S (2014) Introduction: Lipid Profile Minerals and Lipids Profiles in Cardiovascular Disorders in South Asia, 10.1007/978-3-642-34249-3_2, (9-11), . LU N, SHU G, XIE Q, ZHU X, GAO P, ZHOU G, WANG S, WANG L, XI Q, ZHANG Y and JIANG Q (2014) Myristic Acid (MA) Promotes Adipogenic Gene Expression and the Differentiation of Porcine Intramuscular Adipocyte Precursor Cells, Journal of Integrative Agriculture, 10.1016/S2095-3119(13)60664-4, 13:11, (2488-2499), Online publication date: 1-Nov-2014. Zhao W, Yang Y, Lu B, Feng X, He M, Yang Z, Wen J, Zhang Z, Yang Z, Li Q, Ye Z, Gong W and Hu R (2013) Serum high-density lipoprotein cholesterol and progression to arterial stiffness in middle-aged and elderly Chinese, Nutrition, Metabolism and Cardiovascular Diseases, 10.1016/j.numecd.2012.08.001, 23:10, (973-979), Online publication date: 1-Oct-2013. Haley A, Gonzales M, Tarumi T and Tanaka H (2013) Dyslipidemia links obesity to early cerebral neurochemical alterations, Obesity, 10.1002/oby.20332, 21:10, (2007-2013), Online publication date: 1-Oct-2013. Litwak L, Goh S, Hussein Z, Malek R, Prusty V and Khamseh M (2013) Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study, Diabetology & Metabolic Syndrome, 10.1186/1758-5996-5-57, 5:1, Online publication date: 1-Dec-2013. Wei Y, Wang W, He Y, Jiang L, Hou Z, Gao X, Wei C, Cen M, Yang L, Tan A, Yang W, Wang Y and Jin X (2013) Interaction between hypertension and HSP70 variants increase the risk of cerebral ischemia in Chinese Han population: An association study, Gene, 10.1016/j.gene.2012.11.002, 513:2, (239-243), Online publication date: 1-Jan-2013. Reading C, Stickney D, Flores-Riveros J, Destiche D, Ahlem C, Cefalu W and Frincke J (2013) A synthetic anti-inflammatory sterol improves insulin sensitivity in insulin-resistant obese impaired glucose tolerance subjects, Obesity, 10.1002/oby.20207, 21:9, (E343-E349), Online publication date: 1-Sep-2013. Sarbakhsh P, Mehrabi Y, Daneshpour M, Zayeri F and Zarkesh M (2013) Logic regression analysis of association of gene polymorphisms with low HDL: Tehran Lipid and Glucose Study, Gene, 10.1016/j.gene.2012.10.084, 513:2, (278-281), Online publication date: 1-Jan-2013. D V, M V, S. S. B. S and M P (2013) A STUDY OF RISK FACTORS IN MYOCARDIAL INFARCTION IN TRIBAL POPULATION, Journal of Evolution of Medical and Dental Sciences, 10.14260/jemds/758, 2:21, (3746-3755), Online publication date: 27-May-2013. Konno H, Kanai Y, Katagiri M, Watanabe T, Mori A, Ikuta T, Tani H, Fukushima S, Tatefuji T and Shirasawa T (2013) Melinjo ( Gnetum gnemon L.) Seed Extract Decreases Serum Uric Acid Levels in Nonobese Japanese Males: A Randomized Controlled Study , Evidence-Based Complementary and Alternative Medicine, 10.1155/2013/589169, 2013, (1-9), . Toth P, Shammas N, Dippel E and Foreman B (2012) Cardiovascular Disease Textbook of Family Medicine, 10.1016/B978-1-4377-1160-8.10027-2, (478-549), . Mirguet O, Lamotte Y, Donche F, Toum J, Gellibert F, Bouillot A, Gosmini R, Nguyen V, Delannée D, Seal J, Blandel F, Boullay A, Boursier E, Martin S, Brusq J, Krysa G, Riou A, Tellier R, Costaz A, Huet P, Dudit Y, Trottet L, Kirilovsky J and Nicodeme E (2012) From ApoA1 upregulation to BET family bromodomain inhibition: Discovery of I-BET151, Bioorganic & Medicinal Chemistry Letters, 10.1016/j.bmcl.2012.01.125, 22:8, (2963-2967), Online publication date: 1-Apr-2012. Kawamoto R, Tabara Y, Kohara K, Miki T, Abe M and Kusunoki T (2012) Increased high-density lipoprotein cholesterol is associated with a high prevalence of pre-hypertension and hypertension in community-dwelling persons, Endocrine, 10.1007/s12020-012-9625-z, 42:2, (321-328), Online publication date: 1-Oct-2012. Kim S and Van Ta Q (2011) Potential Beneficial Effects of Marine Algal Sterols on Human Health Marine Medicinal Foods - Implications and Applications, Macro and Microalgae, 10.1016/B978-0-12-387669-0.00014-4, (191-198), . Tang K, Lin M, Wu Y and Yan F (2011) Alterations of Serum Lipid and Inflammatory Cytokine Profiles in Patients with Coronary Heart Disease and Chronic Periodontitis: A Pilot Study, Journal of International Medical Research, 10.1177/147323001103900126, 39:1, (238-248), Online publication date: 1-Feb-2011. KHAN M (2006) Cholesterol Encyclopedia of Heart Diseases, 10.1016/B978-012406061-6/50042-4, (233-246), . KHAN M (2006) Dyslipidemia Encyclopedia of Heart Diseases, 10.1016/B978-012406061-6/50055-2, (321-326), . Scirica B and Cannon C (2005) Treatment of Elevated Cholesterol, Circulation, 111:21, (e360-e363), Online publication date: 31-May-2005. Silver M, Chen P, Li R, Cheng C, Wong T, Tai E, Teo Y, Montana G and Williams S (2013) Pathways-Driven Sparse Regression Identifies Pathways and Genes Associated with High-Density Lipoprotein Cholesterol in Two Asian Cohorts, PLoS Genetics, 10.1371/journal.pgen.1003939, 9:11, (e1003939) Syarifah-Noratiqah S, Fairus S, Zulfarina M, Nasrullah Z, Qodriyah H and Naina-Mohamed I (2020) The Effects of Palm Oil on Plasma and Serum Lipid Parameters: A Systematic Review on Animal Intervention Studies, Frontiers in Veterinary Science, 10.3389/fvets.2020.00303, 7 Liu X, Yoon S and Kim I (2020) Growth Performance, Nutrient Digestibility, Blood Profiles, Excreta Microbial Counts, Meat Quality and Organ Weight on Broilers Fed with De-Oiled Lecithin Emulsifier, Animals, 10.3390/ani10030478, 10:3, (478) Eshkoor S, Hamid T, Shahar S and Mun C (2016) Predictive Factors of Severe Stage of Dementia among the Malaysian Elderly, Archive of Gerontology and Geriatrics Research, 10.17352/aggr.000003, 1:1, (006-012) Poles J, Tiozzo E, Konefal J, Rodriguez A, Woolger J and Lewis J (2021) The Effects of a Nutrition Education Program on Dietary Intake and Biomarkers in HIV+ Adults, American Journal of Lifestyle Medicine, 10.1177/1559827620986790, (155982762098679) Adje U, Arute E and Adarighofua M (2017) Knowledge, attitude and practice of community pharmacists in relation to cholesterol screening in Delta State, Nigeria, African Journal of Pharmacy and Pharmacology, 10.5897/AJPP2017.4816, 11:36, (451-457) Lucassen E, Zhao X, Rother K, Mattingly M, Courville A, de Jonge L, Csako G, Cizza G and Goel N (2013) Evening Chronotype Is Associated with Changes in Eating Behavior, More Sleep Apnea, and Increased Stress Hormones in Short Sleeping Obese Individuals, PLoS ONE, 10.1371/journal.pone.0056519, 8:3, (e56519) Flaquer A, Rospleszcz S, Reischl E, Zeilinger S, Prokisch H, Meitinger T, Meisinger C, Peters A, Waldenberger M, Grallert H, Strauch K and Li Q (2015) Mitochondrial GWA Analysis of Lipid Profile Identifies Genetic Variants to Be Associated with HDL Cholesterol and Triglyceride Levels, PLOS ONE, 10.1371/journal.pone.0126294, 10:5, (e0126294) Kaur N, Pandey A, Negi H, Shafiq N, Reddy S, Kaur H, Chadha N, Malhotra S and Bursill C (2014) Effect of HDL-Raising Drugs on Cardiovascular Outcomes: A Systematic Review and Meta-Regression, PLoS ONE, 10.1371/journal.pone.0094585, 9:4, (e94585) February 8, 2005Vol 111, Issue 5 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000154555.07002.CAPMID: 15699268 Originally publishedFebruary 8, 2005 PDF download Advertisement SubjectsEpidemiologyMetabolismPrimary PreventionSecondary Prevention